Nampt-IN-1,1698878-14-6

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Nampt-IN-1

CAS No. : 1698878-14-6

MCE 国际站：Nampt-IN-1

产品活性：Nampt-IN-1 (LSN3154567) 是一种有效的选择性 NAMPT 抑制剂。Nampt-IN-1 抑制纯化的 NAMPT，IC₅₀ 为 3.1 nM。

研究领域：Metabolic Enzyme/Protease

作用靶点：NAMPT

In Vitro: To assess its selectivity, specificity, and effects on cellular NAD⁺ levels, LSN3154567 is characterized in various biochemical and cellular assays. LSN3154567 inhibits purified NAMPT with an IC₅₀ of 3.1 nM. When tested against a panel of human kinases (>100; CEREP Kinase panel), it does not exhibit any significant activity (i.e.: IC₅₀≥1 μM) against the kinases tested except CSF1R (IC₅₀≈0.84 μM). LSN3154567 exhibits a broad spectrum of anticancer activity. To assess its anticancer activity, LSN3154567 is tested against a number of different types of cancer cell lines cultured in the absence or presence of nicotinic acid (NA) (10 μM). LSN3154567 exhibits a potent antiproliferative activity against many cell lines in the absence of NA.

In Vivo: Nampt-IN-1 (LSN3154567) exhibits good physical chemical properties that allow oral dosing. When dosed orally with 2 mg/kg in mice, it has an exposure of 195 nM*hour in the plasma with a peak concentration of 57 nM (at 0.25 hour) and an oral bioavailability of 39%. When dosed intravenously with 2 mg/kg, it has a hepatic clearance of 158.73 mL/min/kg and a volume of distribution at 7.1 L/kg. The half-life of terminal elimination is estimated to be 2.76 hours. LSN3154567 exhibits a dose-dependent inhibition of NAD⁺ formation with estimated TED₅₀ value of 2.0 mg/kg. To assess whether LSN3154567 causes retinopathy, rats are treated with LSN3154567 at 20, 40, and 80 mg/kg for 4 days. No apparent retinopathy is observed. The hematological toxicities are observed. When LSN3154567 is dosed at 20, 40, and 80 mg/kg, the plasma exposures obtained are 8,974, 18,061, and 38,327 M*h, respectively. Thus, LSN3154567 exhibits exposure multiples of respective 3-, 7-, and 14-fold over the exposure (2,701 M*h) required for robust efficacy (≈103%) without NA coadministration. Dogs are treated with LSN3154567 at 1 and 2.5 mg/kg. At these dose levels, the retinal toxicity is observed. Degeneration of the outer nuclear layer occurred in all four animals, but is less pronounced in the animals treated with 1 mg/kg. At the 1 and 2.5 mg/kg dose levels, the plasma exposures are determined to be 1,483 and 2,468 nM*h, respectively.

相关产品：Bioactive Compound Library Plus  |  Metabolism/Protease Compound Library  |  Anti-Cancer Compound Library  |  Heterocyclic Compound Library  |  Highly Selective Inhibitors Library  |  (E)-Daporinad  |  SBI-797812  |  CHS-828  |  OT-82  |  NAT  |  GNE-617  |  GNE-618  |  STF-118804  |  Padnarsertib  |  Teglarinad chloride  |  GPP78  |  Nampt activator-1  |  Nampt activator-2  |  Nampt activator-3  |  CB30865  |  Nampt-IN-3  |  Nampt-IN-5  |  CB 300919  |  LB-60-OF61  |  LB-60-OF61 hydrochloride  |  NAMPT degrader-1  |  Nampt degrader-2  |  NAMPT degrader-3  |  Nampt-IN-10 TFA  |  Nampt-IN-10 trihydrochloride  |  Nampt-IN-7  |  Nampt-IN-8  |  Nampt-IN-9  |  NAMPT/IDO1-IN-1

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds